| heart failure | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Lechat, 1991 | Nebivolol vs placebo | | | | | Wisenbaugh, 1993 | Nebivolol vs placebo | | | all cause death ∞ [NaN; ∞] hospitalisation for heart failure NaN [NaN; NaN] | | nebivolol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Lechat, 1991 | nebivolol 5mg/d (n=6) vs. placebo (n=6) | NYHA 3-4 | Double aveugle Parallel groups Sample size: 6/6 Primary endpoint: Exercise tolerance FU duration: 1.5 month | | Wisenbaugh, 1993 | nebivolol (n=11) vs. placebo (n=13) | patients with dilated idiopathic or ischemic cardiomyopathy (ejection fraction 0.15 to 0.40) in stable NYHA class II or III | double blind Parallel groups Sample size: 11/13 Primary endpoint: Hemodynamics MSI FU duration: 3 mo | | SENIORS, 2005 | nebivolol (titrated from 1.25 mg once
daily to 10 mg once daily) (n=1067) vs. placebo (n=1061) | patients aged 70 years with a
history of heart failure (hospital admission for heart failure within the previous year
or known ejection fraction 35%), | Double blind Parallel groups Sample size: 1067/1061 Primary endpoint: FU duration: 21 months |
|
